Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
ACS Medicinal Chemistry Letters|December 18, 2020
Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory ActivityRamsay E Beveridge, Heidi Ackerly Wallweber, Avi Ashkenazi, et al.Bioorganic & Medicinal Chemistry Letters|November 7, 2017
Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitorsAaron Smith, Zhi-Jie Ni, Daniel Poon, et al.Bioorganic & Medicinal Chemistry Letters|November 25, 2017
Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300Kwong Wah Lai, F Anthony Romero, Vickie Tsui, et al.Journal of Medicinal Chemistry|May 15, 2024
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma ModelMarie-Gabrielle Braun, Avi Ashkenazi, Ramsay E Beveridge, et al.Journal of Medicinal Chemistry|November 21, 2017
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) InhibitorsSarah M Bronner, Jeremy Murray, F Anthony Romero, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating CancerMatthew T Burger, Sabina Pecchi, Allan Wagman, et al.Chemmedchem|November 2, 2019
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo ActivityThomas H Pillow, Pragya Adhikari, Robert A Blake, et al.Journal of Medicinal Chemistry|February 17, 2021
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular PropertiesPeter S Dragovich, Thomas H Pillow, Robert A Blake, et al.Proceedings of the National Academy of Sciences of the United States of America|August 3, 2019
Disruption of IRE1α through its kinase domain attenuates multiple myelomaJonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, et al.Journal of Medicinal Chemistry|February 17, 2021
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor EfficacyPeter S Dragovich, Thomas H Pillow, Robert A Blake, et al.Pageof 6